Skip to content
PubMed This is a summary of 39 peer-reviewed journal articles Updated
Neurology · Autosomal Dominant Striatal Degeneration

Autosomal Dominant Striatal Degeneration: A Patient Guide

At a Glance

Autosomal dominant striatal degeneration is an ultra-rare inherited movement disorder caused by PDE8B gene changes. It usually progresses slowly and can cause stiffness, slowed movement, and balance problems, while therapy, safety planning, genetic counseling, and monitoring support daily life.

Autosomal Dominant Striatal Degeneration (ADSD) is an ultra-rare genetic movement disorder that primarily affects the striatum, a deep-seated region of the brain responsible for coordinating smooth, purposeful movement [1]. Caused by mutations in the PDE8B gene, this condition disrupts the way brain cells process signals, which is thought to lead to a gradual loss of neurons in this critical command center [2]. Because it is so rare, many patients spend years seeking an answer, often finding that their symptoms are initially confused with more common neurological disorders. Understanding that this is a specific, distinct genetic condition is the first step toward building a management plan tailored to your needs [3].

Living with ADSD means managing a pattern of symptoms known as parkinsonism, which typically includes muscle stiffness and a significant slowing of physical movement [3]. Unlike typical Parkinson’s disease, ADSD often progresses without the classic resting tremor, and it may be accompanied by ataxia, or a lack of coordination and balance [2]. While the term “degeneration” can be frightening, the condition is characterized by its slowly progressive nature. However, reported cases have generally progressed slowly, but the range of progression and effects on lifespan are not well established [3]. The underlying course is usually slow, but complications can still be serious, so it is important to seek urgent or emergency care for choking or breathing difficulty, a significant fall or head injury, or sudden one-sided weakness or confusion [4].

The path forward focuses on proactive, multidisciplinary care that addresses the physical challenges of the condition while prioritizing safety. Because the inheritance pattern is autosomal dominant, each child of an affected person has a 50% chance of inheriting the pathogenic variant (though penetrance, age at onset, and variant-specific risk are poorly defined), making genetic counseling a vital resource for the entire family [3]. Management is centered on a team approach, utilizing physical and occupational therapy to maintain strength and home safety, alongside speech therapy to monitor for changes in swallowing or communication [5]. By focusing on regular monitoring—particularly for “red flags” like falls or swallowing difficulties—you can take an active role in managing the condition and preserving your quality of life for years to come [6].

Common questions in this guide

What is autosomal dominant striatal degeneration?
Autosomal dominant striatal degeneration, or ADSD, is an ultra-rare inherited movement disorder caused by a change in the PDE8B gene. It affects the striatum, a brain region that helps coordinate purposeful movement, and can lead to stiffness, slowed movement, and balance or coordination problems.
What symptoms can ADSD cause?
Commonly described features include muscle stiffness, marked slowness of movement, and ataxia, which means problems with coordination and balance. Unlike typical Parkinson’s disease, ADSD may occur without a classic resting tremor; swallowing or communication changes may also need monitoring.
How is ADSD inherited, and what does it mean for my children?
ADSD follows an autosomal dominant inheritance pattern, so each child of an affected person has a 50% chance of inheriting the pathogenic PDE8B variant. The chance of developing symptoms, age at onset, and variant-specific risk are not well established, so genetic counseling can help families understand their individual situation.
How can doctors confirm that ADSD is caused by a PDE8B variant?
A clinician can use genetic testing to look for a pathogenic variant in PDE8B and interpret the result alongside your symptoms and neurological examination. A movement-disorder specialist or genetics professional can help distinguish this finding from changes in other genes, such as PDE10A or genes associated with Parkinson’s disease.
What therapies can help people living with ADSD?
Physical therapy can support strength and mobility, while occupational therapy can help with daily activities and home safety. Speech therapy can monitor communication and swallowing, and a multidisciplinary team can adjust support as needs change.
When is ADSD an emergency?
Seek urgent or emergency care for choking or breathing difficulty, a significant fall or head injury, or sudden one-sided weakness or confusion. Less urgent changes, such as gradually worsening balance or swallowing, should still be reported to the treating clinician so they can be assessed.
How quickly does ADSD progress?
Reported cases generally describe slow progression, but the range of progression and effects on lifespan are not well established because ADSD is so rare. Regular follow-up can help the care team track movement, swallowing, communication, and safety needs over time.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since this condition is ultra-rare, can you help me find a movement disorder center that specializes in genetic parkinsonism?
  2. 2.How can we confirm that my mutation is in the PDE8B gene and not the more common PDE10A or Parkinson's genes?
  3. 3.What is the best way to assemble a team of physical, occupational, and speech therapists who understand my specific mobility needs?
  4. 4.What objective signs should we track during my regular check-ups to monitor the progression of my symptoms?
  5. 5.What specific symptoms or events should prompt me to seek emergency care versus calling your office?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (6)
  1. 1

    The Emerging Role of Phosphodiesterases in Movement Disorders.

    Erro R, Mencacci NE, Bhatia KP

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(10)):2225-2243 doi:10.1002/mds.28686.

    PMID: 34155691
  2. 2

    A novel mutation of PDE8B Gene in a Japanese family with autosomal-dominant striatal degeneration.

    Azuma R, Ishikawa K, Hirata K, et al.

    Movement disorders : official journal of the Movement Disorder Society 2015; (30(14)):1964-7 doi:10.1002/mds.26345.

    PMID: 26769607
  3. 3

    Clinical findings of autosomal-dominant striatal degeneration and PDE8B mutation screening in parkinsonism and related disorders.

    Ni J, Yi X, Liu Z, et al.

    Parkinsonism & related disorders 2019; (69()):94-98 doi:10.1016/j.parkreldis.2019.11.002.

    PMID: 31726290
  4. 4

    Speech and Language outcomes in Auditory Neuropathy Spectrum Disorder (ANSD) children managed with amplification.

    Ramanathan D, Mahomva C, Goldberg D, et al.

    American journal of otolaryngology 2023; (44(2)):103753 doi:10.1016/j.amjoto.2022.103753.

    PMID: 36577168
  5. 5

    Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.

    Saffie Awad P, Teixeira-Dos-Santos D, Santos-Lobato BL, et al.

    Movement disorders : official journal of the Movement Disorder Society 2024; (39(1)):6-16 doi:10.1002/mds.29614.

    PMID: 37921246
  6. 6

    Combined use of a double-lumen tube and Fogarty catheter to prevent the endobronchial spread of infection: a case report.

    Kim J, Lee H, Park H, Jeong CY

    Korean journal of anesthesiology 2016; (69(6)):619-622 doi:10.4097/kjae.2016.69.6.619.

    PMID: 27924204

This page is for informational purposes only and does not constitute medical advice. Your neurologist and genetic counselor can help interpret your PDE8B result and plan individualized therapy and emergency guidance.

Get notified when new evidence is published on Autosomal dominant striatal neurodegeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.